RecruitingNot ApplicableNCT05788744

Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

Implementing Non-invasive Circulating Tumor DNA and Circular DNA Analysis in Patients With Localized Pancreatic Cancer to Optimize the Pre- and Postoperative Treatment: Predicting Recurrence and Survival and Changing Prognosis Over Time

Sponsor

Copenhagen University Hospital at Herlev

Enrollment

1,000 participants

Start Date

Jan 1, 2023

Study Type

INTERVENTIONAL

Conditions

Resectable Pancreatic Cancer

Summary

The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is testing whether liquid biopsy blood tests — including ctDNA (circulating tumor DNA) and circular DNA — can detect cancer recurrence early in patients with localized pancreatic cancer who have had surgery. Pancreatic cancer often comes back after surgery, and earlier detection through blood tests could improve outcomes. **You may be eligible if...** - You have pancreatic ductal adenocarcinoma (PDAC) at stage I–III - You are scheduled for or have already had surgery to remove your tumor - There are no signs of cancer recurrence at your 4-month post-surgery scan (for one sub-study) **You may NOT be eligible if...** - You have had another cancer (other than certain skin cancers) in the past 3 years - You are unlikely to complete follow-up visits or comply with the study protocol Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.